Mackenzie Financial’s Stemline Therapeutics, Inc. STML Stock Holding History

Mackenzie Financial’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-36,899	Closed	-$400K	–	753
2016 Q3	$400K	Sell	36,899 -149,370	-80%	-$1.21M	﹤0.01%	523
2016 Q2	$1.26M	Sell	186,269 -7,106	-4%	-$44.9K	0.01%	552
2016 Q1	$901K	Sell	193,375 -15,600	-7%	-$76.2K	0.01%	532
2015 Q4	$1.32M	Buy	208,975 +475	+0.2%	+$3.85K	0.01%	486
2015 Q3	$1.84M	Buy	208,500 +43,000	+26%	+$451K	0.01%	425
2015 Q2	$1.95M	Buy	165,500 +66,100	+66%	+$918K	0.01%	435
2015 Q1	$1.44M	Buy	99,400 +35,300	+55%	+$540K	0.01%	487
2014 Q4	$1.09M	Buy	+64,100	New	+$924K	0.01%	520

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Mackenzie Financial's STML Position: Q4 2016 in Review

Mackenzie Financial sold out of Stemline Therapeutics, Inc. (STML) in Q4 2016, closing a stake of 36,899 shares — an estimated $400K sold.

Mackenzie Financial first reported a position in STML in Q4 2014 and held it in 8 quarters. The position peaked at $1.95M in Q2 2015. 74 funds tracked by Wall St. Rank hold STML as of Q4 2016.

Mackenzie Financial reported no remaining Stemline Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Mackenzie Financial sold 36,899 Stemline Therapeutics, Inc. shares in Q4 2016, an estimated $400K.
Mackenzie Financial first reported a position in Stemline Therapeutics, Inc. in Q4 2014 and held it in 8 quarters.
Mackenzie Financial's Stemline Therapeutics, Inc. position peaked at $1.95M in Q2 2015.
74 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2016.

Based on Mackenzie Financial's 13F filing for Q4 2016, filed 14 Feb 2017.